FDA Approves Daily Pill to Treat Low Libido in Women After Menopause

Health & LifestyleNews
799

Listen to article (english)

Translate to Spanish or other 102 languages!

On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved the medication Addyi (flibanserin) for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women under the age of 65. Image for illustration purposes
On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved the medication Addyi (flibanserin) for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women under the age of 65. Image for illustration purposes

Mega Doctor News

- Advertisement -

Medical News Today

On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved the medication Addyi (flibanserin) for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women under the age of 65.

Addyi was previously approved in 2015 for the treatment of HSDD in premenopausal women. Premenopause or “before” menopause refers to the reproductive time in a cisgender woman’s life when they have regular menstrual cycles.

- Advertisement -

Follow the link below to Medical News Today to read the full story:

https://www.medicalnewstoday.com/articles/fda-approves-daily-pill-treat-low-libido-women-postmenopause-explainer?utm_term=feature&utm_source=Sailthru%20Email&utm_medium=Email&utm_campaign=MNT%20Daily%20News&utm_content=2025-12-19&apid=&rvid=4ba4ec80177cae00eabc43b8bc6648d598c4a356d104663735777e0a0f8b5c9f

Information source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Heart Association Highlights 2025’s Major Research Findings
Next article
From Patient to Hero: Isaac Garza Delivers 2,089 Smiles This Holiday Season

More Articles

DHR Health Raises Over $520K at 20th “Fishing for Hope” Event

DHR Health made a big splash at the 20th Annual “Fishing for Hope” Tournament, held on August 22 at Jim’s Pier in South Padre Island, raising an impressive grand total of $524,130.

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. 

STHS Behavioral Marks Suicide Prevention Month with Community Chalk Event

Every 11 minutes, someone in the United States dies by suicide, according to the Centers for Disease Control and Prevention (CDC), making it one of the nation's leading causes of death.

STHS & Prominence Health Hosting “Senior Living Seminar” on Malnutrition, Sept. 4th

Malnutrition is often an invisible health concern, quietly undermining an older adult's strength, independence and overall quality of life. Yet its warning signs are frequently overlooked or mistaken for a normal part of aging.
- Advertisement -